New Approaches for the Management of Diabetes: Practical Considerations for Clinicians

SGLT2 Inhibitors in Phase 3 Trials

Dapagliflozin†: Reduction in FPG at Week 24 Across Studies

Dapagliflozin* 10 mg vs Metformin XR vs Combination Therapy: HbA1c at Week 24

Dapagliflozin† 10 mg vs Glipizide as Add-on to Metformin

Dapagliflozin†: Change in Body Weight at Week 24

Summary: Efficacy of SGLT2 Inhibitors*

Elements of Decision-Making for Achieving Glycemic Goals

ADA / EASD Position Statement: Managing Hyperglycemia in T2DM

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)